½ÃÀåÁ¶»çº¸°í¼
ÀÇ·á±â±â
ÀǾàǰ
¸ÅÆ®¸®¾ó
Åë½Å/IT
»ê¾÷¿ë±â°è
¿¡³ÊÁö/ȯ°æ
ÀüÀÚºÎǰ/¹ÝµµÃ¼
ÀÚµ¿Â÷
Ç×°ø¿ìÁÖ/¹æÀ§
½Äǰ/À½·á
ÀϹݼҺñÀç
ÀÎÇÁ¶ó
±ÝÀ¶/¹ðÅ·
¿¬°£Á¤º¸¼ºñ½º
¸ÂÃãÇü½ÃÀåÁ¶»ç
±Û·Î¹úÆÄÆ®³Ê
¸ÞÀϸµ¼ºñ½º
ÀÌ¿ë¾È³»
ȸ»ç¼Ò°³
ºñ±³¸®½ºÆ®
īƮ
¹®ÀÇ
Ȩ
>
±Û·Î¹úÆÄÆ®³Ê
> La Merie Publishing
Ä«Å×°í¸®
ÀÇ·á±â±â
ÀǾàǰ
¸ÅÆ®¸®¾ó
ÀÚµ¿Â÷
»ê¾÷¿ë±â°è
¿¡³ÊÁö/ȯ°æ
ÀüÀÚºÎǰ/¹ÝµµÃ¼
Åë½Å/IT
Ç×°ø¿ìÁÖ/¹æÀ§
½Äǰ/À½·á
ÀϹݼҺñÀç
ÀÎÇÁ¶ó
±ÝÀ¶/¹ðÅ·
La Merie Publishing
½ºÆäÀÎ ¹Ù¸£¼¿·Î³ª¿¡ º»»ç¸¦ µÐ La Merie´Â ¹ÙÀÌ¿À Å×Å©³î·¯Áö ¹× Á¦¾à »ê¾÷¿¡ ´ëÇÑ ¸®¼Ä¡¸¦ Àü¹®À¸·Î Çϰí ÀÖ½À´Ï´Ù.
°Ë»ö
Á¦¸ñ°Ë»ö
1
-
7
¸®ºä (Àüü£º
7
°Ç)
Á¤·Ä
¹ßÇàÀÏ
ÇѱÛÁ¦¸ñ
¿µ¹®Á¦¸ñ
°¡°Ý
Ç¥½Ã °Ç¼ö
25
50
100
Ŭ¶ó¿ìµò(Claudin) 18.2 : Ç¥Àû ¸é¿ªÄ¡·á - ¾÷°è °üÁ¡À¸·ÎºÎÅÍÀÇ ÀÌÇØ°ü°èÀÚ, ¾àÁ¦ ¸ð´Þ¸®Æ¼, ÆÄÀÌÇÁ¶óÀÎ, ºñÁî´Ï½º ±âȸ ºÐ¼®
Claudin 18.2 - Targeted Immunotherapy: A Landscape Analysis of Stakeholders, Drug Modalities, Pipeline and Business Opportunities from an Industry Perspective
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
1328018
¹ßÇàÀÏ
2023³â 08¿ù
ÆäÀÌÁö Á¤º¸
267 Pages
°¡°Ý
EUR 2,150 ->
£Ü 3,076,000
¼¼°èÀÇ Ç×ü ½ÃÀå : Ç¥Àû, ±â¼ú, ÆÄÀÌÇÁ¶óÀÎ µ¥ÀÌÅͺ£À̽º(¿¬°£ ±¸µ¶)
Antibody Target, Technology & Pipeline Database: 1-Year Subscription
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
1262973
¹ßÇàÁ¤º¸
¿¬°£±¸µ¶
ÆäÀÌÁö Á¤º¸
°¡°Ý
EUR 1,600 ->
£Ü 2,289,000
Ű¸Þ¶ó Ç׿ø ¼ö¿ëü-´ë½Ä¼¼Æ÷(CAR-M) ½ÃÀå : ÀÌÇØ°ü°èÀÚ, ±â¼ú, ÆÄÀÌÇÁ¶óÀÎ, Á¦ÈÞ, ÀÚ±Ý Á¶´Þ
CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
1213672
¹ßÇàÀÏ
2023³â 02¿ù
ÆäÀÌÁö Á¤º¸
96 Pages
°¡°Ý
EUR 1,800 ->
£Ü 2,575,000
RNA¸¦ Ç¥ÀûÀ¸·Î ÇÑ ½Å±Ô ¾àÁ¦ ¸ð´Þ¸®Æ¼ ½ÃÀå : RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting µî¿¡ ±âÃʸ¦ µÐ RNA Ÿ°Ù ½Å¾à ¸ð´Þ¸®Æ¼
RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: Landscape Analysis of Technologies, Targets, Business & Financing
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
1152702
¹ßÇàÀÏ
2022³â 11¿ù
ÆäÀÌÁö Á¤º¸
418 Pages
°¡°Ý
EUR 2,350 ->
£Ü 3,363,000
¸®Æ÷Æ® ¹øµé : Ŭ¶ó¿ìµò 6 , CDH17, ROR1, GPRC5D Ç¥Àû Ä¡·á ½ÃÀå - Ç¥Àû ¹ßÇö °³¿ä, ¾à¹° ¸ð´Þ¸®Æ¼ÀÇ ¾ÈÀü¼º°ú À¯È¿¼º, ÆÄÀÌÇÁ¶óÀÎ ¸®ºä ¹× °æÀï ±¸µµ ºÐ¼®
4 Reports Bundle - Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
1097878
¹ßÇàÀÏ
2022³â 07¿ù
ÆäÀÌÁö Á¤º¸
263 Pages
°¡°Ý
EUR 1,800 ->
£Ü 2,575,000
ROR1 Ç¥Àû Ä¡·á ½ÃÀå : Ç¥Àû ¹ßÇö °³¿ä, ¾à¹° ¸ð´Þ¸®Æ¼ÀÇ ¾ÈÀü¼º°ú À¯È¿¼º, ÆÄÀÌÇÁ¶óÀÎ ¸®ºä ¹× °æÀï ±¸µµ ºÐ¼®
ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
1097877
¹ßÇàÀÏ
2022³â 06¿ù
ÆäÀÌÁö Á¤º¸
116 Pages
°¡°Ý
EUR 1,050 ->
£Ü 1,502,000
ÇÁ·ÎÅ×¾ÆÁ», ¸®¼ÒÁ», ¿ÀÅäÆÄÁö °æ·Î¿¡ ÀÇÇÑ Ç¥Àû ´Ü¹éÁú ºÐÇØ(TDP)(2022³â) : ¾÷°è »óȲ ºÐ¼® - ÀÌÇØ°ü°èÀÚ, ±â¼ú, ÆÄÀÌÇÁ¶óÀÎ, Á¦ÈÞ, ÀÚ±Ý Á¶´Þ
Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: An Industry Landscape Analysis of Stakeholders, Technologies, Pipeline, Partnering and Financing
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
1064487
¹ßÇàÀÏ
2022³â 03¿ù
ÆäÀÌÁö Á¤º¸
553 Pages
°¡°Ý
EUR 2,450 ->
£Ü 3,506,000
»ó±â ÀÚ·á ÀÌ¿ÜÀÇ
La Merie Publishing
ÀÚ·áµµ ÁÖ¹® °¡´ÉÇÏ´Ï
¹®ÀÇ
ÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.